Cannapharmarx, Inc. (CPMD): Net Income
-$11.13M
Year ended 2025-12-31
-$11.32M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$11.13M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$9.91M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $3.69M | n/m | 2025-04-10, From 2023-01-01 |
| 2022-12-31 | -$8.53M | n/m | 2023-09-01, From 2022-01-01 |
| 2021-12-31 | -$8.83M | n/m | 2023-09-01, From 2021-01-01 |
| 2020-12-31 | -$19.89M | n/m | 2022-04-15, From 2020-01-01 |
| 2019-12-31 | -$20.45M | n/m | 2021-04-14, From 2019-01-01 |
| 2018-12-31 | -$3.09M | n/m | 2020-05-27, From 2018-01-01 |
| 2017-12-31 | -$6.6K | n/m | 2019-04-03, From 2017-01-01 |
| 2016-12-31 | -$1.00M | n/m | 2019-04-03, From 2016-01-01 |
| 2015-12-31 | -$11.74M | n/m | 2018-09-14, From 2015-01-01 |
| 2014-12-31 | -$3.98M | n/m | 2018-09-11, From 2014-01-01 |
| 2013-12-31 | -$94.4K | n/m | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | -$98.1K | n/m | 2014-02-06, From 2012-01-01 |
| 2011-12-31 | -$99.7K | n/m | 2014-02-06, From 2011-01-01 |
| 2010-12-31 | $575.4K | +428.6% | 2012-03-14, From 2010-01-01 |
| 2009-12-31 | $108.9K | n/a | 2011-06-30, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$11.13M | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$60.16M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | -$2.91M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$28.62M | n/m |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | -$7.12M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$69.69M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | -$22.70M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$13.45M | n/m |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | -$6.21M | n/m |
Compare CPMD, NWBO, ATXI, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗